DelveInsight’s, “Heart Failure Pipeline Insight 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in the Heart Failure pipeline landscape. It covers the pipeline drug profiles, including Heart Failure clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Heart Failure Pipeline Report
- DelveInsight’s Heart Failure Pipeline report depicts a robust space with 75+ active players working to develop 90+ pipeline therapies for Heart Failure treatment.
- The leading Heart Failure Companies includes Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
- Promising Heart Failure Pipeline Therapies include CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
- January 2024: AstraZeneca announced a study of Phase 2 clinical trials for AZD3427. This study is intended to assess the ability of AZD3427 to reduce pulmonary vascular resistance (PVR) after 24 weeks of treatment in participants with heart failure (HF) and pulmonary hypertension (PH) Group 2.
- January 2024: Bayer announced a study of Phase 3 clinical trials for Finerenone (BAY94-8862). The purpose of this study is to evaluate the effect of finerenone compared to placebo (a tablet without active substance) in the reduction of cardiovascular death (generally meaning death due to disease of the heart or blood vessels) and total Heart Failure (HF) events, including HF hospitalization and urgent visits for HF(generally meaning a hospital stay or urgent presentation to a healthcare unit due to worsening symptoms of heart failure) in patients suffering from HF with an ejection fraction greater than or equal to 40%.
- January 2024: Novartis Pharmaceuticals announced a study of Phase 2 clinical trials for Sacubitril/valsartan. This is a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Request a sample and discover the recent advances in Heart Failure Treatment Drugs @ Heart Failure Pipeline Outlook Report
In the Heart Failure pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, Heart Failure clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Heart Failure Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations.
Find out more about the Heart Failure Diagnosis and Treatment of patients @ Heart Failure Ongoing Clinical Trials Analysis
Heart Failure Emerging Drugs
- Tirzepatide: Eli Lilly and Company
- Finerenone (BAY94-8862): Bayer
- CardiAMP Cell Therapy: BioCardia
- Firibastat: Quantum Genomics
- HU 6: Rivus Pharmaceuticals
Heart Failure Therapeutics Assessment
There are approx. 75+ Heart Failure companies which are developing the therapies for Heart Failure. The Heart Failure companies which have their Heart Failure drug candidates in the most advanced stage, i.e. Phase III include, Eli Lilly and Company.
Heart Failure Route of Administration
Heart Failure pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
Discover more about the list of Heart Failure FDA-approved drugs @ Heart Failure Treatment Landscape
Heart Failure Products have been categorized under various Molecule types such as
- Oligonucleotide
- Peptide
- Small molecule
Scope of the Heart Failure Pipeline Report
- Coverage- Global
- Heart Failure Companies- Zensun (Shanghai) Sci & Tech, Windtree Therapeutics, TreeFrog Therapeutics, Torrent Pharmaceuticals, Tenaya Therapeutics, Tasly Pharmaceuticals, Sulfagenix, Stealth BioTherapeutics, SQ Innovation, Shanghai Hongyitang Biopharmaceutical Technology, scPharmaceuticals, Sardocor, Sana Biotechnology, Salubris Biotherapeutics, Roche, Rivus Pharmaceuticals, Ribomic, Renova Therapeutics, Relaxera, Regeneron Pharmaceuticals, Recardio, Quantum Genomics, Procella Therapeutics, Precigen, Pfizer, Paradigm biopharmaceuticals, Palatin Technologies, Orizuru Therapeutics, Olatec Therapeutics, Novo Nordisk, Metcela, Mesoblast Inc., Merck & Co, Lexicon Pharmaceuticals, Janssen Research & Development, Ionis Pharmaceuticals, InvivoSciences, Intra-Cellular Therapies, Innolife, Imbria Pharmaceuticals, Imara Inc, Hyloris Pharmaceuticals, Help Therapeutics, Heartseed, HAYA Therapeutics, GlaxoSmithKline, GB Sciences, Fujifilm Corporation, Evotec SE, Eli Lilly and Company, Edgewise Therapeutics, DiNAQOR, Cytokinetics, CUORiPS, Chong Kun Dang, Cardurion Pharmaceuticals, Cardiora, Cardior Pharmaceuticals, Cardiol Therapeutics, CardioCell, Bristol-Myers Squibb, Bristol Myers Squibb, Boryung Pharmaceutical, BlueRock Therapeutics, BioCardia, BIAL, Berlin Cures, BenevolentAI, Bayer, Athersys, AstraZeneca, Asklepios Biopharmaceutical, Antlia Biosciences, AnaCardio, AliveGen, Actelion Pharmaceuticals, and others.
- Heart Failure Pipeline Therapies- CXL-1020, Strata 1 CXL-1020, Ularitide, Allogeneic Mesenchymal Bone Marrow Cells (aMBMC), Lactated Ringer’s Solution, Bisoprolol, Empagliflozin, Lixivaptan, and others.
- Heart Failure Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Heart Failure Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Dive deep into rich insights for Heart Failure Emerging Therapies and Ongoing Clinical Trials; visit @ Heart Failure Emerging Therapies and Companies
Table of Content
- Introduction
- Heart Failure Executive Summary
- Heart Failure Overview
- Heart Failure Pipeline Therapeutics
- Heart Failure Therapeutic Assessment
- Heart Failure – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Tirzepatide: Eli Lilly and Company
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- HU 6: Rivus Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HiCM 188: Help Therapeutics
- Drug profiles in the detailed report…..
- Inactive Products
- Heart Failure Collaborations Assessment- Licensing / Partnering / Funding
- Heart Failure Unmet Needs
- Heart Failure Market Drivers and Barriers
- Appendix
Got Queries? Find out the related information on Heart Failure Mergers and acquisitions, Heart Failure Licensing Activities @ Heart Failure Emerging Drugs, and Recent Trends
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services